OncoLog

[OncoLog @OncoLogNews]

This Twitter account will no longer be actively tweeting new information, effective Aug. 30. Please follow @MDAndersonNews to get our latest news for physicians.

[OncoLog @OncoLogNews]

This Twitter account will no longer be actively tweeting new information, effective Aug. 30. Please follow @MDAndersonNews to get our latest news for physicians.

[OncoLog @OncoLogNews]

This Twitter account will no longer be actively tweeting new information, effective Aug. 30. Please follow @MDAndersonNews to get our latest news for physicians.

[OncoLog @OncoLogNews]

The August 2018 issue will be OncoLog’s final issue. https://t.co/WqxjdBjJIe

Thanks for following us and reading OncoLog. To continue keeping up with the latest MD Anderson research, please follow @CancerFrontline and @MDAndersonNews.
#EndCancer

[OncoLog @OncoLogNews]

House Call: Cancer and Post-Traumatic Stress Disorder
Help is available for cancer patients with PTSD
https://t.co/615wOXfST0
#EndCancer

[OncoLog @OncoLogNews]

Therapy Preserves Swallowing Function
New trial tests different swallowing therapy regimens for head and neck cancer patients undergoing radiation therapy
https://t.co/Ta6dKNJDnl

[OncoLog @OncoLogNews]

Esophageal, Pharyngoesophageal Reconstruction
Advanced surgical techniques restore digestive continuity for head and neck cancer patients
https://t.co/eCS5xX4CGI
#EndCancer

[OncoLog @OncoLogNews]

Image-Guided Cordotomy for Cancer Pain
Computed tomography–guided cordotomy relieves cancer-related refractory pain
https://t.co/ckq4vl4HKJ
#EndCancer
#opioidcrisis

[OncoLog @OncoLogNews]

High-Dose Radiation Therapy for Pancreatic Cancer
Trial tests whether radiomodulating agent GC4419 can enable higher doses of SBRT
#EndCancer
https://t.co/mB2G8778Sy

[OncoLog @OncoLogNews]

Come to the @MDAndersonNews Cancer Survivorship Conference Sept. 13-14. Learn more at https://t.co/lMUeTWIKFt.

[OncoLog @OncoLogNews]

Managing High-Risk Breast Lesions
Strong provider recommendation for preventive therapy increases its use in women with lobular carcinoma in situ, atypical hyperplasia #bcsm https://t.co/MZJjy9IcWL

[OncoLog @OncoLogNews]

Erdafitinib has favorable response rate in advanced bladder cancers, including those that do not respond to immunotherapy #blcsm https://t.co/u47BnhonZB

[OncoLog @OncoLogNews]

Targeted Therapies Matched to Tumor-Specific Mutations Prolong Survival
https://t.co/LpX4KZE9cl

[OncoLog @OncoLogNews]

What the National Cancer Institute Does
Resources for cancer patients, caregivers, physicians, researchers https://t.co/DQ5OVVzk5I #EndCancer

[OncoLog @OncoLogNews]

Aerosolized Gemcitabine for Pulmonary Metastases
Clinical trial tests novel chemotherapy delivery system for patients with lung metastases from osteosarcoma or other solid tumors #srcb https://t.co/RyuqY86J0S

[OncoLog @OncoLogNews]

Managing High-Risk Breast Lesions
Strong provider recommendation for preventive therapy increases its use in women with lobular carcinoma in situ, atypical hyperplasia #bcsm https://t.co/MZJjy9IcWL

[OncoLog @OncoLogNews]

FGFR Inhibition for Bladder Cancer
Erdafitinib has favorable response rate in advanced bladder cancers, including those that do not respond to immunotherapy #blcsm https://t.co/u47Bnh6MB1

[OncoLog @OncoLogNews]

5th Annual Art and Science of Managing the New Melanoma Landscape Conference on September 28-29, 2018 https://t.co/AZpzvKoRzH

[OncoLog @OncoLogNews]

Targeted Therapies Matched to Tumor-Specific Mutations Prolong Survival
https://t.co/LpX4KZE9cl

[OncoLog @OncoLogNews]

What the National Cancer Institute Does
Resources for cancer patients, caregivers, physicians, researchers https://t.co/DQ5OVVzk5I #EndCancer